Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      University College of London London (UCL); London School of Hygiene and Tropical Medicine (LSHTM); Erasmus University Medical Center Rotterdam (Erasmus MC); Donostia International Physics Center - DIPC (SPAIN); Donostia International Physics Center (DIPC); Universidad del País Vasco Espainia / Euskal Herriko Unibertsitatea España = University of the Basque Country Spain = Université du pays basque Espagne (UPV / EHU)-Universidad del País Vasco Espainia / Euskal Herriko Unibertsitatea España = University of the Basque Country Spain = Université du pays basque Espagne (UPV / EHU); Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Universitat de Barcelona (UB); Centre Hospitalier Université Laval Quebec (CHUL); CHU de Québec–Université Laval; Université Laval Québec (ULaval)-Université Laval Québec (ULaval); Karolinska Institutet Stockholm; University of Toronto; University of Cambridge UK (CAM); Università degli Studi di Brescia = University of Brescia (UniBs); University of Western Ontario (UWO); Universitätsklinikum Tübingen - University Hospital of Tübingen; Eberhard Karls Universität Tübingen = University of Tübingen; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven); Lusófona University Lisbon; University of Oxford; University of Manchester Manchester; McGill University = Université McGill Montréal, Canada; Institut du Cerveau = Paris Brain Institute (ICM); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS); CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Fondazione IRCCS Istituto Neurologico "Carlo Besta"; Universidade de Coimbra = University of Coimbra Portugal (UC); Lille Neurosciences & Cognition - U 1172 (LilNCog); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Ludwig Maximilian University Munich = Ludwig Maximilians Universität München (LMU); University of Ulm (UUlm); Università degli Studi di Firenze = University of Florence = Université de Florence (UniFI); ANR-11-LABX-0009,DISTALZ,Développement de stratégies innovantes pour une approche transdisciplinaire de la maladie d'Alzheime(2011); ANR-14-CE15-0016,PREV-DEMALS,Prédire pour prévenir les démences frontotemporales (DFT) et la sclérose latérale amyotrophique (SLA)(2014)
    • بيانات النشر:
      CCSD
      BMJ Publishing Group
    • الموضوع:
      2021
    • Collection:
      Inserm: HAL (Institut national de la santé et de la recherche médicale)
    • نبذة مختصرة :
      International audience ; Background: Therapeutic trials are now underway in genetic forms of frontotemporal dementia (FTD) but clinical outcome measures are limited. The two most commonly used measures, the Clinical Dementia Rating (CDR)+National Alzheimer's Disease Coordinating Center (NACC) Frontotemporal Lobar Degeneration (FTLD) and the FTD Rating Scale (FRS), have yet to be compared in detail in the genetic forms of FTD.Methods: The CDR+NACC FTLD and FRS were assessed cross-sectionally in 725 consecutively recruited participants from the Genetic FTD Initiative: 457 mutation carriers (77 microtubule-associated protein tau (MAPT), 187 GRN, 193 C9orf72) and 268 family members without mutations (non-carrier control group). 231 mutation carriers (51 MAPT, 92 GRN, 88 C9orf72) and 145 non-carriers had available longitudinal data at a follow-up time point.Results: Cross-sectionally, the mean FRS score was lower in all genetic groups compared with controls: GRN mutation carriers mean 83.4 (SD 27.0), MAPT mutation carriers 78.2 (28.8), C9orf72 mutation carriers 71.0 (34.0), controls 96.2 (7.7), p<0.001 for all comparisons, while the mean CDR+NACC FTLD Sum of Boxes was significantly higher in all genetic groups: GRN mutation carriers mean 2.6 (5.2), MAPT mutation carriers 3.2 (5.6), C9orf72 mutation carriers 4.2 (6.2), controls 0.2 (0.6), p<0.001 for all comparisons. Mean FRS score decreased and CDR+NACC FTLD Sum of Boxes increased with increasing disease severity within each individual genetic group. FRS and CDR+NACC FTLD Sum of Boxes scores were strongly negatively correlated across all mutation carriers (rs=-0.77, p<0.001) and within each genetic group (rs=-0.67 to -0.81, p<0.001 in each group). Nonetheless, discrepancies in disease staging were seen between the scales, and with each scale and clinician-judged symptomatic status. Longitudinally, annualised change in both FRS and CDR+NACC FTLD Sum of Boxes scores initially increased with disease severity level before decreasing in those with the most ...
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/34353857; PUBMED: 34353857
    • الرقم المعرف:
      10.1136/jnnp-2021-326868
    • الدخول الالكتروني :
      https://hal.sorbonne-universite.fr/hal-03343515
      https://hal.sorbonne-universite.fr/hal-03343515v1/document
      https://hal.sorbonne-universite.fr/hal-03343515v1/file/jnnp-2021-326868.full.pdf
      https://doi.org/10.1136/jnnp-2021-326868
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.9E081703